The Unveiling of the Most Comprehensive miRNA Database in Cancer
Miras Biotechnology, a company specializing in oligonucleotides, particularly miRNA molecules, unveiled namiRa, the most comprehensive miRNA database in cancer, in conjunction with National Research and Technology Week. This database, the result of five years of research and the review of approximately ten thousand international scientific articles, provides data on 1,110 different miRNA molecules across 35 types of cancer.The event, which was attended by the Deputy Minister of Research and Technology of the Ministry of Health, Treatment, and Medical Education, featured the CEO of Miras Biotechnology, a company based at the Royan Biotechnology Incubator, who introduced this international database. Dr. Sharif Moradi, a faculty member of Royan Institute and the founder of the company, explained that the name namiRa is derived from "Mir" (referring to miRNA) and the immortality of cancer, as cancer cells are rapidly proliferating and immortal cells that continuously increase in number through successive cell divisions.
The namiRa database allows researchers to perform searches in three ways: by cancer type, by miRNA name, or by a combination of both. The database provides precise information on miRNA expression in various cancers, methods of miRNA identification (such as qRT-PCR, Microarray, Small RNA Sequencing), and the results of functional analyses of miRNAs. Additionally, researchers can explore the effects of miRNAs on various biological phenomena, including apoptosis, cell proliferation, survival, chemotherapy resistance, cell cycle arrest, and cancer metastasis.
A prominent feature of this database is the provision of an accurate gene regulatory network for each miRNA in each cancer type, automatically generated by the database. This schematic map is available for download in both JPG and PDF formats, enabling researchers to use it for more detailed analyses. As the most comprehensive miRNA database in the world, namiRa serves as a highly valuable tool for researchers in the field of cancer.
Publish date: 2024/12/22
